| Typicality: | 0.399 |
| Saliency: | 0.350 |
| by the food and drug administration | 8 | other |
| in 2010 | 4 | temporal |
| in the spine | 2 | location |
| gel → be approved by → the fda | 7 |
| gel → be → approved | 3 |
| gel → be approved for → use | 3 |
| negative | neutral | positive |
| 0.198 | 0.460 | 0.342 |
| Raw frequency | 13 |
| Normalized frequency | 0.350 |
| Modifier score | 0.500 |
| Perplexity | 72.206 |